Asset Details
Do you wish to reserve the book?
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
Do you wish to request the book?
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
2010
Overview
We studied the relationship between
JAK2
(V617F) mutant allele burden and clinical phenotype, disease progression and survival in patients with polycythemia vera (PV). The percentage of granulocyte mutant alleles was evaluated using a quantitative real-time polymerase chain reaction-based allelic discrimination assay. Of the 338 patients enrolled in this prospective study, 320 (94.7%) carried the
JAK2
(V617F) mutation. Direct relationships were found between mutant allele burden and hemoglobin concentration (
P
=0.001), white blood cell count (
P
=0.001), spleen size (
P
=0.001) and age-adjusted bone marrow cellularity (
P
=0.002), while an inverse relationship was found with platelet count (
P
<0.001). During the study period, eight patients progressed to post-PV myelofibrosis (MF) (all carrying >50% mutant alleles), while 10 patients developed acute myeloid leukemia (AML). The mutant allele burden was significantly related to the risk of developing myelofibrosis (
P
=0.029) and retained its significant effect also in multivariable analysis (
P
=0.03). By contrast, the risk of developing AML as well as that of thrombosis was not significantly related to mutant allele burden. Leukocytosis did not affect thrombosis, MF, leukemia or survival. In conclusion, a
JAK2
(V617F) allele burden >50% represents a risk factor for progression to MF in PV.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 692/499
/ Age
/ Aged
/ Alleles
/ Biological and medical sciences
/ Blood
/ Cell Transformation, Neoplastic - genetics
/ Cloning
/ Complications and side effects
/ Female
/ Hematologic and hematopoietic diseases
/ Humans
/ Ischemia
/ Leukemia
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Male
/ Medicine
/ Mutants
/ Mutation
/ Oncology
/ Patients
/ Polycythemia Vera - complications
/ Polycythemia Vera - genetics
/ Polycythemia Vera - pathology
/ Primary Myelofibrosis - genetics
/ Spleen
/ Survival
